ClinicalTrials.gg
CompletedNCT06256536Updated Feb 23, 2024

A Study of GZR18 Injection in Chinese Obese/Overweight Patients

A Phase 1/2 interventional study of GZR18 and Placebo in Obesity and Overweight, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Jul 2022, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
9th of 15
60 · median 140
Started
2022
the only one that year
Phase 1/2
Only one
of the 15
Registered
1st of 15
by date
Lead sponsor
5 of 15
Gan and Lee Pharmaceuticals, USA

Among the 15 studies testing bofanglutide in Obesity, this one is the 9th largest by enrollment, is the only one that started in 2022, is the only one in phase 1/2, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

The study was a multicenter, randomized, double-blind, placebo-controlled phase Ib/IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in Chinese adult obese/overweight patients. This study is divided into Part A and Part B, which are to be conducted simultaneously.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male or female aged 18-65 years (inclusive);

      1. Obese subjects: ≥ 28.0 kg/m2; or overweight subjects: 24.0 ≤ BMI \< 28.0 kg/m2 with at least one comorbidity;
      1. Able to understand the procedures and methods in this study; willing to complete the study in strict accordance with the clinical study protocol and sign the ICF voluntarily.

Exclusion criteria

Exclusion Criteria:

    1. Suspicion that the subject may be allergic to any study drug or ingredient or congener from the investigator.

      1. Subjects with body weight change > 5.0% for any reason (diet, exercise, etc.) within 12 weeks prior to screening.
      1. Heart rate \< 50 beats/min or > 100 beats/min on 12-lead at screening.
      1. Presence of the following 12-lead ECG abnormalities at screening.
      1. Alcohol abuse within 6 months prior to screening, or reluctance to stop alcohol abuse throughout the study, or a positive breath alcohol test result at screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    GZR18

    GZR18 injection s.c.

    Drug: GZR18

  • Placebo comparator
    Placebo

    Placebo injection s.c.

    Other: Placebo

Interventions

  • DrugGZR18

    0.6 mg-30 mg

  • OtherPlacebo

    administered the same volume as GZR18

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and serious adverse events

    Time frame: 38 weeks

  2. Changes in weight from baseline to the end of treatment

    Time frame: 35 weeks

Secondary outcomes

  1. trough concentrations following consecutive doses

    Time frame: 35 weeks

  2. Changes in Body mass index (BMI) from baseline to the end of treatment

    Time frame: 35 weeks

  3. Changes in Percentage of reduction in weight (%) from baseline to the end of treatment

    Time frame: 35 weeks

  4. Changes in Waist circumference from baseline to the end of treatment

    Time frame: 35 weeks

  5. Proportion of subjects with ≥5% reduction in body weight from baseline.

    Time frame: 35 weeks

07

Study locations

1 site
  • Gan & Lee Pharmaceuticals Co., Ltd
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Oct 2023, 15 months.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 13, 2024
StartActual
Jul 14, 2022
Primary completionActual
Oct 22, 2023
CompletionActual
Oct 22, 2023
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06256536
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Jul 14, 2022
Primary completion
Oct 22, 2023
Completion
Oct 22, 2023
Last update
Feb 23, 2024

Study contacts

Liyuan Zhao, Ph.D
study director · Gan & Lee Pharmaceuticals.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion